Literature DB >> 11890881

Animal models for scleroderma: an update.

Yan Zhang1, Anita C Gilliam.   

Abstract

Scleroderma is a progressive debilitating fibrosing disease that may involve multiple organs. The pathogenesis of this disease remains unclear. Animal models for scleroderma are valuable for studying the pathogenesis of this complex disorder and for testing potential treatments for human scleroderma. There are several animal models available that exhibit important features of scleroderma, each with an emphasis on different aspects of the disease (tissue fibrosis, inflammation, vascular injury, or immunologic changes). These models can be separated into several categories in which fibrosis is induced by external agents (vinyl chloride, bleomycin), by breeding of mutant strain combinations (integrin alpha 1 null mouse, MRL/lpr gamma R-/- mouse), and by transplantation of disparate immune cells (sclerodermatous graft versus host disease). In addition, there are spontaneous mutations (UCD 200 chicken, tight skin mouse) in which fibrosis occurs. The tight skin mouse has been reviewed recently. This review discusses the other animal models and some interventions in each.

Entities:  

Mesh:

Year:  2002        PMID: 11890881     DOI: 10.1007/s11926-002-0011-3

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  51 in total

1.  Effect of interferon-gamma on experimental scleroderma induced by bleomycin.

Authors:  T Yamamoto; S Takagawa; M Kuroda; K Nishioka
Journal:  Arch Dermatol Res       Date:  2000-07       Impact factor: 3.017

Review 2.  Animal models of scleroderma: contrasts and comparisons.

Authors:  J Van de Water; S A Jimenez; M E Gershwin
Journal:  Int Rev Immunol       Date:  1995       Impact factor: 5.311

Review 3.  TGF-beta latency: biological significance and mechanisms of activation.

Authors:  P E Gleizes; J S Munger; I Nunes; J G Harpel; R Mazzieri; I Noguera; D B Rifkin
Journal:  Stem Cells       Date:  1997       Impact factor: 6.277

4.  A syndrome resembling progressive systemic sclerosis after bone marrow transplantation. A model for scleroderma?

Authors:  D E Furst; P J Clements; P Graze; R Gale; N Roberts
Journal:  Arthritis Rheum       Date:  1979-08

Review 5.  Genetics of systemic autoimmunity in mouse models of lupus.

Authors:  D H Kono; A N Theofilopoulos
Journal:  Int Rev Immunol       Date:  2000       Impact factor: 5.311

6.  Murine graft vs host disease. A model for study of mechanisms that generate autoantibodies to ribonucleoproteins.

Authors:  C Gelpi; J L Rodriguez-Sanchez; M A Martinez; J Craft; J A Hardin
Journal:  J Immunol       Date:  1988-06-15       Impact factor: 5.422

7.  The tight skin 2 mouse. An animal model of scleroderma displaying cutaneous fibrosis and mononuclear cell infiltration.

Authors:  P J Christner; J Peters; D Hawkins; L D Siracusa; S A Jiménez
Journal:  Arthritis Rheum       Date:  1995-12

8.  Monocytes of patients wiht systemic sclerosis (scleroderma spontaneously release in vitro increased amounts of superoxide anion.

Authors:  P Sambo; L Jannino; M Candela; A Salvi; M Donini; S Dusi; M M Luchetti; A Gabrielli
Journal:  J Invest Dermatol       Date:  1999-01       Impact factor: 8.551

9.  Chronic graft-versus-host disease (GVHD) as a model for scleroderma. I. Description of model systems.

Authors:  B D Jaffee; H N Claman
Journal:  Cell Immunol       Date:  1983-04-01       Impact factor: 4.868

10.  Specificity of antinuclear antibodies in scleroderma-like chronic graft-versus-host disease: clinical correlation and histocompatibility locus antigen association.

Authors:  S A Bell; H Faust; J Mittermüller; H J Kolb; M Meurer
Journal:  Br J Dermatol       Date:  1996-05       Impact factor: 9.302

View more
  6 in total

1.  A convenient method for producing the bleomycin-induced mouse model of scleroderma by weekly injections using a methylcellulose gel.

Authors:  Jae-Bum Jun; Jang Kyoung Kim; Young-In Na; Se Min Jang; Seung Sam Paik; Yong-Hee Kim
Journal:  Rheumatol Int       Date:  2011-03-30       Impact factor: 2.631

Review 2.  Animal models in scleroderma.

Authors:  Stephen H Clark
Journal:  Curr Rheumatol Rep       Date:  2005-04       Impact factor: 4.592

3.  Efficacy of rapamycin in scleroderma: a case study.

Authors:  Levi Fried; Robert S Kirsner; Sulochana Bhandarkar; Jack L Arbiser
Journal:  Lymphat Res Biol       Date:  2008       Impact factor: 2.589

Review 4.  Is scleroderma a vasculopathy?

Authors:  Jo Nadine Fleming; Richard A Nash; William M Mahoney; Stephen Mark Schwartz
Journal:  Curr Rheumatol Rep       Date:  2009-04       Impact factor: 4.592

Review 5.  Surgical approaches to create murine models of human wound healing.

Authors:  Victor W Wong; Michael Sorkin; Jason P Glotzbach; Michael T Longaker; Geoffrey C Gurtner
Journal:  J Biomed Biotechnol       Date:  2010-12-01

6.  Halofuginone down-regulates Smad3 expression and inhibits the TGFbeta-induced expression of fibrotic markers in human corneal fibroblasts.

Authors:  Elizabeth F Nelson; Craig W Huang; Jillian M Ewel; Angela A Chang; Ching Yuan
Journal:  Mol Vis       Date:  2012-02-18       Impact factor: 2.367

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.